Paxlovid efficacy ‘not established’ for low-risk patients: study

Professor Allen Cheng says the findings support current use of antivirals in high-risk individuals
Rachel Fieldhouse
Professor Allen Cheng
Professor Allen Cheng.

Nirmatrelvir-ritonavir is no better than placebo for resolving symptoms in patients who are at low risk for severe COVID-19, results from an international study suggest.

The phase II/III trial showed no significant difference between nirmatrelvir-ritonavir (Paxlovid) and placebo for time to symptom alleviation in patients with confirmed COVID-19.